Document is current
Any future updates will be listed below
-
Authors
Turner, Jessica A. https://orcid.org/0000-0003-0076-8434
Calhoun, Vince D. https://orcid.org/0000-0001-9058-0747
Thompson, Paul M. https://orcid.org/0000-0002-4720-8867
Jahanshad, Neda https://orcid.org/0000-0003-4401-8950
Ching, Christopher R. K.
Thomopoulos, Sophia I. https://orcid.org/0000-0002-0046-4070
Verner, Eric https://orcid.org/0000-0002-1461-4818
Strauss, Gregory P. https://orcid.org/0000-0002-7218-5169
Ahmed, Anthony O.
Turner, Matthew D. https://orcid.org/0000-0002-4417-1042
Basodi, Sunitha
Ford, Judith M.
Mathalon, Daniel H.
Preda, Adrian https://orcid.org/0000-0003-3373-2438
Belger, Aysenil https://orcid.org/0000-0003-2687-1966
Mueller, Bryon A. https://orcid.org/0000-0003-2429-0391
Lim, Kelvin O. https://orcid.org/0000-0002-2390-7268
van Erp, Theo G. M. https://orcid.org/0000-0002-2465-2797
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (1R01MH121246)
National Institute of Mental Health (1U24 RR021992)
National Institute on Drug Abuse (R01DA040487)
National Institute on Drug Abuse (R01DA049238)
National Institutes of Health (R01MH116147)
National Institutes of Health (1U24 RR025736)
National Institutes of Health (R01MH117601)
U.S. Department of Veterans Affairs (I01 CX0004971)
- License Information
-
More Information
Article History
Accepted: 19 November 2021
First Online: 30 November 2021
Declarations
:
: PMT, NJ, and CRKC received grant support from Biogen, Inc., for research unrelated to this manuscript. GPS has consulted or spoken for Lundbeck, Acadia, and Minerva pharmaceutical companies in return for honorarium. DHM is a consultant for Boehringer Ingelheim and Cadent Therapeutics. AP has consulted for Boehringer Ingelheim and is a consultant for Guidepoint and GLG Group.
